Trial · NCT00780676
Personalized Treatment Selection for Metastatic Breast Cancer
NCT00780676, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2015-07-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Personalized Treatment Selection for Metastatic Breast Cancer. Trials, record NCT00780676. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00780676
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Personalized Treatment Selection for Metastatic Breast Cancer
- NCT number
- NCT00780676
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 97 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Breast Cancer
- Interventions
- Dasatinib, AZD6244
- First posted
- 2008-10-28
- Last updated
- 2020-09-03
- Results first posted
- 2015-07-20
- Limitations and caveats
- Study terminated according to early stopping rules.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months) | Tumor status assessed every 8 weeks during therapy, up to 6 months | Rate of participants with response complete, partial response or stable disease categorized by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Radiological response assessments must be repeated every 8 weeks during therapy. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months) | Tumor status assessed every 8 weeks during therapy, up to 6 months | Selumetinib pathway predictor groups (both MEK pathway activity predictor positive and MEK pathway predictor negative) had no patients assigned to either group, and only treated participants (30) included in analysis. | Percentage of Participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months) | Dasatinib Sensitivity Signature | 0 | Percentage of Participants | ||
| Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months) | SRC Pathway Activity Signature | 0 | Percentage of Participants | ||
| Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months) | Dasatinib Target Index | 7.7 | Percentage of Participants |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib Sensitivity Signature | 9 | |
| Overall Study | STARTED | SRC Pathway Activity Signature | 8 | |
| Overall Study | STARTED | Dasatinib Target Index | 13 | |
| Overall Study | STARTED | MEK Pathway Activity Predictor Positive | 0 | |
| Overall Study | STARTED | MEK Pathway Predictor Negative | 0 | |
| Overall Study | COMPLETED | Dasatinib Sensitivity Signature | 9 | |
| Overall Study | COMPLETED | SRC Pathway Activity Signature | 8 | |
| Overall Study | COMPLETED | Dasatinib Target Index | 13 | |
| Overall Study | COMPLETED | MEK Pathway Activity Predictor Positive | 0 | |
| Overall Study | COMPLETED | MEK Pathway Predictor Negative | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events55
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Dasatinib 100 mg | 1 | 30 | |
| other | Activated partial thromboplastin time prolonged | Blood and lymphatic system disorders | Dasatinib 100 mg | 1 | 30 | |
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Dasatinib 100 mg | 3 | 30 | |
| other | Alkaline phosphatase increased | Metabolism and nutrition disorders | Dasatinib 100 mg | 3 | 30 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Dasatinib 100 mg | 2 | 30 | |
| other | Anorexia | Gastrointestinal disorders | Dasatinib 100 mg | 1 | 30 | |
| other | Anxiety | Psychiatric disorders | Dasatinib 100 mg | 1 | 30 | |
| other | Arthritis | Musculoskeletal and connective tissue disorders | Dasatinib 100 mg | 1 | 30 | |
| other | Aspartate aminotransferase increased | Metabolism and nutrition disorders | Dasatinib 100 mg | 4 | 30 | |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Dasatinib 100 mg | 1 | 30 |
1 to 10 of 55Source ClinicalTrials.gov
See all 55 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib 100 mg | ||
| Total, other adverse events | Dasatinib 100 mg | 27 | 30 |
| Total, serious adverse events | Dasatinib 100 mg | 3 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00780676
GET https://conductscience.org/api/trials/v1/NCT00780676/events?page=2